Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Granaticin B,Azacitidine,Venetoclax
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lin BioScience Receives U.S. FDA Fast Track Designation for LBS-007
Details : LBS-007 is a natural, non-ATP cell cycle inhibitor targeting a broad array of cancers. It is being evaluated for the treatment of patients with relapsed or resistant acute leukaemias.
Product Name : LBS-007
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 27, 2024
Lead Product(s) : Granaticin B,Azacitidine,Venetoclax
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable